DK3145916T3 - Imidazolderivater som formylpeptidreceptormodulatorer - Google Patents
Imidazolderivater som formylpeptidreceptormodulatorer Download PDFInfo
- Publication number
- DK3145916T3 DK3145916T3 DK15726498.7T DK15726498T DK3145916T3 DK 3145916 T3 DK3145916 T3 DK 3145916T3 DK 15726498 T DK15726498 T DK 15726498T DK 3145916 T3 DK3145916 T3 DK 3145916T3
- Authority
- DK
- Denmark
- Prior art keywords
- receptor modulators
- formylpeptide receptor
- imidazold
- derivatives
- imidazold derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462001188P | 2014-05-21 | 2014-05-21 | |
| PCT/US2015/032069 WO2015179707A1 (en) | 2014-05-21 | 2015-05-21 | Imidazole derivatives as formyl peptide receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3145916T3 true DK3145916T3 (da) | 2020-05-11 |
Family
ID=53276329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15726498.7T DK3145916T3 (da) | 2014-05-21 | 2015-05-21 | Imidazolderivater som formylpeptidreceptormodulatorer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10301269B2 (enExample) |
| EP (1) | EP3145916B1 (enExample) |
| JP (1) | JP6660889B2 (enExample) |
| KR (1) | KR20170005121A (enExample) |
| CN (1) | CN106458921B (enExample) |
| AU (2) | AU2015264021B2 (enExample) |
| BR (1) | BR112016027133A8 (enExample) |
| CA (1) | CA2948876A1 (enExample) |
| DK (1) | DK3145916T3 (enExample) |
| ES (1) | ES2788700T3 (enExample) |
| RU (1) | RU2748652C2 (enExample) |
| WO (1) | WO2015179707A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| HUE040145T2 (hu) | 2011-10-26 | 2019-02-28 | Allergan Inc | N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok |
| AU2014226001B2 (en) * | 2013-03-06 | 2018-12-06 | Allergan, Inc. | Use of agonists of Formyl peptide receptor 2 for treating dermatological diseases |
| BR112016011417A8 (pt) | 2013-11-21 | 2020-05-05 | Allergan Inc | derivados de fenilcarbamatos como moduladores do receptor de formil peptídeo, composição farmacêutica, e seus usos |
| KR20170005121A (ko) | 2014-05-21 | 2017-01-11 | 알러간, 인코포레이티드 | 폼일 펩타이드 수용체 조절제로서의 이미다졸 유도체 |
| WO2017180323A1 (en) | 2016-04-12 | 2017-10-19 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2533210A1 (fr) | 1982-09-17 | 1984-03-23 | Lyon I Universite Claude | Edulcorants de synthese |
| WO2005047899A2 (en) | 2003-11-07 | 2005-05-26 | Acadia Pharmaceuticals Inc. | Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation |
| BRPI0506662B8 (pt) | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
| WO2007086584A1 (ja) * | 2006-01-30 | 2007-08-02 | Meiji Seika Kaisha, Ltd. | 新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤 |
| WO2008023159A1 (en) * | 2006-08-24 | 2008-02-28 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| WO2009000748A1 (en) | 2007-06-27 | 2008-12-31 | Solvay Fluor Gmbh | Preparation of compounds with a perfluoroalkylsulfonyl group |
| JP2010533158A (ja) * | 2007-07-09 | 2010-10-21 | アストラゼネカ アクチボラグ | 化合物類−９４５ |
| CN101998680B (zh) * | 2009-08-24 | 2016-01-13 | 中兴通讯股份有限公司 | 帧序列号的发送方法及节点b和服务无线网络控制器 |
| AU2011336973A1 (en) | 2010-12-03 | 2013-07-11 | Allergan, Inc. | Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity |
| WO2012109544A1 (en) | 2011-02-11 | 2012-08-16 | Allergan, Inc. | Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators |
| EP2731931A1 (en) | 2011-07-11 | 2014-05-21 | Allergan, Inc. | Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators |
| HUE040145T2 (hu) * | 2011-10-26 | 2019-02-28 | Allergan Inc | N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok |
| US8541577B2 (en) | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| US8492556B2 (en) * | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| EP2814815A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators |
| SG11201406629VA (en) | 2012-04-16 | 2014-11-27 | Allergan Inc | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| EP2964213B1 (en) | 2013-03-06 | 2020-11-04 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
| AU2014226001B2 (en) | 2013-03-06 | 2018-12-06 | Allergan, Inc. | Use of agonists of Formyl peptide receptor 2 for treating dermatological diseases |
| KR102313757B1 (ko) | 2013-07-16 | 2021-10-18 | 알러간, 인코포레이티드 | 펩타이드 수용체 조절제로서의 n-우레아 치환된 아미노산의 유도체 |
| BR112016011417A8 (pt) | 2013-11-21 | 2020-05-05 | Allergan Inc | derivados de fenilcarbamatos como moduladores do receptor de formil peptídeo, composição farmacêutica, e seus usos |
| US9920013B2 (en) | 2014-01-29 | 2018-03-20 | Allergan, Inc. | 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators |
| US9604934B2 (en) | 2014-01-29 | 2017-03-28 | Allergan, Inc. | Urea hydantoin derivatives as formyl peptide modulators |
| US9663457B2 (en) | 2014-04-09 | 2017-05-30 | Allergan, Inc. | Carbamoyl hydrazine derivatives as formyl peptide modulators |
| KR20170005121A (ko) | 2014-05-21 | 2017-01-11 | 알러간, 인코포레이티드 | 폼일 펩타이드 수용체 조절제로서의 이미다졸 유도체 |
| AU2017241767B2 (en) | 2016-03-28 | 2021-07-22 | Allergan, Inc. | Phenyl urea derivatives as N-formyl peptide receptor modulators |
| WO2017180323A1 (en) | 2016-04-12 | 2017-10-19 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
-
2015
- 2015-05-21 KR KR1020167035670A patent/KR20170005121A/ko not_active Ceased
- 2015-05-21 DK DK15726498.7T patent/DK3145916T3/da active
- 2015-05-21 CN CN201580026983.9A patent/CN106458921B/zh not_active Expired - Fee Related
- 2015-05-21 US US15/312,367 patent/US10301269B2/en active Active
- 2015-05-21 ES ES15726498T patent/ES2788700T3/es active Active
- 2015-05-21 EP EP15726498.7A patent/EP3145916B1/en active Active
- 2015-05-21 WO PCT/US2015/032069 patent/WO2015179707A1/en not_active Ceased
- 2015-05-21 AU AU2015264021A patent/AU2015264021B2/en not_active Ceased
- 2015-05-21 BR BR112016027133A patent/BR112016027133A8/pt not_active Application Discontinuation
- 2015-05-21 JP JP2016568605A patent/JP6660889B2/ja not_active Expired - Fee Related
- 2015-05-21 RU RU2016145596A patent/RU2748652C2/ru active
- 2015-05-21 CA CA2948876A patent/CA2948876A1/en not_active Abandoned
-
2019
- 2019-05-22 US US16/419,317 patent/US10800744B2/en active Active
-
2020
- 2020-05-25 AU AU2020203420A patent/AU2020203420B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20200115346A1 (en) | 2020-04-16 |
| CN106458921A (zh) | 2017-02-22 |
| RU2748652C2 (ru) | 2021-05-28 |
| RU2016145596A3 (enExample) | 2018-11-19 |
| AU2020203420B2 (en) | 2021-12-16 |
| AU2015264021B2 (en) | 2020-02-27 |
| WO2015179707A1 (en) | 2015-11-26 |
| CN106458921B (zh) | 2020-03-24 |
| ES2788700T3 (es) | 2020-10-22 |
| JP2017520528A (ja) | 2017-07-27 |
| BR112016027133A2 (pt) | 2017-08-15 |
| KR20170005121A (ko) | 2017-01-11 |
| CA2948876A1 (en) | 2015-11-26 |
| AU2020203420A1 (en) | 2020-06-11 |
| RU2016145596A (ru) | 2018-06-21 |
| US10301269B2 (en) | 2019-05-28 |
| EP3145916B1 (en) | 2020-02-12 |
| AU2015264021A1 (en) | 2016-12-01 |
| US20170096401A1 (en) | 2017-04-06 |
| JP6660889B2 (ja) | 2020-03-11 |
| EP3145916A1 (en) | 2017-03-29 |
| US10800744B2 (en) | 2020-10-13 |
| BR112016027133A8 (pt) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43382A (fr) | Modulateurs des récepteurs des chimiokines | |
| DK3394033T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
| DK3131902T3 (da) | Forbindelser som ROR-gamma-modulatorer | |
| DK3094631T4 (da) | Pyrimidinyloxybenzenderivater som herbicider | |
| DK3490986T3 (da) | Piperidin-cxcr7-receptormodulatorer | |
| DK3229810T3 (da) | Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler | |
| DK3294713T3 (da) | Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer | |
| DK3097107T3 (da) | Diaryl-makrocykler som modulatorer for proteinkinaser | |
| MA53943A (fr) | Modulateurs de ror-gamma | |
| DK3377483T3 (da) | N-substituerede indolderivater som pge2-receptormodulatorer | |
| LT3134402T (lt) | 4-amino-imidazochinolino junginiai | |
| LT3204359T (lt) | Tetrahidroizochinolino dariniai | |
| DK3331863T3 (da) | Hidtil ukendte forbindelser som ror-gamma-modulatorer | |
| DK3125898T3 (da) | Farmakofor til trail-induktion | |
| DK3256462T3 (da) | Substituerede 2-thioimidazolyl-carboxamider som skadedyrsbekæmpelsesmiddel | |
| HUE048321T2 (hu) | Karabazol származékok | |
| DK3231803T3 (da) | Dihydroindolizinonderivat | |
| DK3153508T3 (da) | Naphthofuranderivater til anvendelse som anticancermidler | |
| EP3140315C0 (en) | NEW CATH2 DERIVATIVES | |
| DK3131898T3 (da) | Fluoroalkylfluorenderivativer | |
| IL247140A0 (en) | Pyrazines modulators of gpr6 | |
| DK3792251T3 (da) | Hidtil ukendte sulfonylaminobenzamidforbindelser som anthelmintika | |
| LT3347349T (lt) | Fluorindolo dariniai kaip muskarininio m1 receptoriaus teigiami alosteriniai moduliatoriai | |
| PL3137460T3 (pl) | Pochodne diheterocyklu połączonego cykloalkilem | |
| LT3097076T (lt) | Nauji cip-eikozanoidų dariniai |